Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Rapeseed oil stanol esters** are chemical compounds created by esterifying plant stanols (hydrogenated phytosterols) with fatty acids derived from rapeseed oil. They are primarily used as dietary agents to lower low-density lipoprotein (LDL) cholesterol. The mechanism of action is based on interfering with the micellar solubilisation of cholesterol in the gut, which decreases intestinal cholesterol absorption and increases the excretion of cholesterol and plant sterols in feces[2][4][7][9]. This results in reduced serum LDL cholesterol, typically by 10–15% in adults with standard doses, and up to 50% with higher doses in animal models[4][7][9]. Rapeseed oil stanol esters have been found to be safe in both adults and children, with no significant side effects except in rare disorders like sitosterolemia and short bowel syndrome[3][12]. They are commonly formulated into spreads, capsules, or functional foods targeting cardiovascular risk reduction, and may improve endothelial function and arterial stiffness alongside their cholesterol-lowering effect[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rapeseed oil stanol esters.